Perspective Therapeutics Inc Stock Price, News & Analysis

Perspective Therapeutics (NYSE AMERICAN: CATX) reported Q3 2024 financial results and business updates. The company has $267.8 million in cash and investments, expected to fund operations into mid-2026. Key developments include advancing [212Pb]VMT01 trials in melanoma patients and [212Pb]VMT-α-NET in neuroendocrine tumors. The company started shipping from a second manufacturing facility in Somerset, New Jersey, and purchased additional facilities in Houston, Chicago, and Los Angeles. Q3 2024 showed a net loss of $15.1 million ($0.21 per share), with research and development expenses at $12.0 million and general administrative expenses at $7.0 million.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, will report its third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the market closes. The press release will be available in the newsroom section of the Company's website.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on cancer treatments, has announced its participation in four major investor conferences this November. The company will attend the Truist Securities BioPharma Symposium (Nov 7) in New York for one-on-one meetings, the UBS Global Healthcare Conference (Nov 13) in California featuring a fireside chat, the Stifel Healthcare Conference (Nov 18) in New York with a fireside chat, and the Jefferies London Healthcare Conference (Nov 19-21) for one-on-one meetings. Webcasts of applicable events will be available live and archived for 90 days on the company's investor website.

Perspective Therapeutics (NYSE AMERICAN: CATX) presented six updates on its radiopharmaceutical programs at the 37th Annual EANM Congress in Hamburg. The presentations included preclinical studies and first-in-human imaging data for [212Pb]Pb-PSV359, showing strong tumor uptake and anti-tumor efficacy. Updates on [212Pb]Pb-VMT-α-NET revealed promising interim clinical results in NET patients, with confirmed tumor responses in six of ten GEP-NETs patients. The presentations also covered biodistribution studies, chelator evaluations, and development of imaging surrogates for therapeutic radiopharmaceuticals.

Perspective Therapeutics (NYSE AMERICAN: CATX) has begun shipping investigational products from its new radiopharmaceutical manufacturing facility in Somerset, New Jersey. This state-of-the-art facility is now operational, supporting VMT-α-NET clinical studies alongside the existing Coralville, Iowa facility. With three cGMP-compliant manufacturing suites, it's expected to meet future clinical trial and commercial demands in the Northeastern U.S.

The Somerset facility, acquired from Lantheus Holdings in March 2024, previously produced FDA-approved Azedra for rare adrenal gland tumors. This milestone comes just seven months after acquisition, accelerating Perspective's efforts in delivering investigational products and potential new radiopharmaceutical therapies. The company aims to replicate this approach, adding strategic sites to enhance its network supporting key treatment hubs across the U.S.

Perspective Therapeutics (NYSE AMERICAN: CATX) presented initial results from its Phase 1/2a study of [212Pb]VMT01, a MC1R-targeted radiopharmaceutical therapy for melanoma, at the 21st International Congress of the Society for Melanoma Research. Key findings include:

1. Safety: No dose-limiting toxicities observed at 3.0 and 5.0 mCi doses.

2. Efficacy: Prolonged progression-free survival and tumor response in heavily pretreated patients at the 3.0 mCi dose.

3. The trial is progressing with a lower 1.5 mCi dose to optimize immunostimulatory activities, both as monotherapy and in combination with nivolumab.

4. The Safety Monitoring Committee recommended exploring the 1.5 mCi dose level as a single agent and in combination with nivolumab.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research (SMR). The event will be held on October 10-13, 2024, in New Orleans, Louisiana.

The study, titled “First in Human Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Melanoma (MM),” marks the company's first scientific presentation of clinical data from a company-sponsored study. CEO Thijs Spoor highlighted the ongoing exploration of the optimal dose of [212Pb]VMT01 in metastatic melanoma, both as a single agent and in combination with nivolumab.

Perspective will host a conference call on October 11, 2024, at 9am ET to review the data presented at SMR. Details will be available on the Events page of the company's website.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, announced its participation in two upcoming events: the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit on October 8, 2024, in New York, NY, and the JonesResearch Virtual Radiopharma Day on October 29, 2024.

At the Oppenheimer Summit, Perspective's senior management will participate in two panel discussions: 'The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes' from 9:30 a.m. to 10:30 a.m. ET, and 'Supply Chain Challenges and Controversies: Ac225 Availability, Pb212 Logistics, The Last Mile' from 10:50 a.m. to 11:35 a.m. ET. They will also give a company presentation at 1:30 p.m. ET.

The JonesResearch event will feature a panel format. Webcasts for both events will be accessible live and archived for 90 days on the Perspective website's Investors page.

Perspective Therapeutics (NYSE AMERICAN: CATX) will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) in Hamburg, Germany, from October 19-23, 2024. The company will showcase several presentations, including:

1. Preclinical evaluation and first-in-human imaging of [203/212Pb]Pb-PSV359, targeting fibroblast activation protein-alpha (FAP).

2. Impact of molar activity on [203Pb]Pb-VMT-α-NET biodistribution in neuroendocrine tumor xenografts.

3. Interim results of 212Pb-VMT-α-NET Targeted Alpha Therapy in metastatic gastro-entero-pancreatic neuroendocrine tumors.

4. Image-guided evaluation of 212Pb-VMT-α-NET in metastatic neuroendocrine tumors.

The presentations will include updated analyses from investigator-led clinical research and preclinical studies, focusing on novel radiopharmaceutical treatments for various cancers.